| Name | Title | Contact Details |
|---|
Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.
Alucent Biomedical, Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah and is the first company to bring a novel, locally delivered biotechnology treatment to a market traditionally dominated by medical device solutions. Alucent was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.
At Prevail Therapeutics, we are pioneering innovative therapies that aim to cure neurodegenerative disorders, such as Parkinson`s disease. Our mission is to translate breakthrough advances in human genetics and gene therapy technology into life-changing medicines that slow, stop and reverse the neurodegenerative process. Our novel gene therapies target patients with urgent unmet needs, where there are currently no available therapies to change the progressive course of their diseases. Prevail was formed in 2017, and as an emerging biotechnology company, we are growing rapidly. We are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.
Lg Technologies Inc is a Bakersville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client`s needs.